iRhythm Technologies Announces Third Quarter 2023 Financial Results

Rhea-AI Summary

iRhythm Technologies, Inc. reported financial results for Q3 2023, with revenue of $124.6 million, a 20.0% increase compared to Q3 2022. Gross margin declined by 210 basis points. Cash, cash equivalents, and marketable securities were $158.5 million as of September 30, 2023. The company increased its fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million. iRhythm achieved record registration volumes, launched the next generation Zio monitor, opened a Global Business Services center in the Philippines, and published cost-effectiveness data for mSToPs in Circulation: Cardiovascular Quality and Outcomes. Upcoming data presentations will be held at the American Heart Association (AHA) in November 2023.

Positive

• Revenue increased by 20.0% in Q3 2023 compared to Q3 2022.
• The company increased its fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million.
• Record registration volumes were achieved during the quarter.
• The next generation Zio monitor was launched with enhanced Zio service.
• iRhythm opened a Global Business Services center in the Philippines.
• Cost-effectiveness data for mSToPs was published, demonstrating high value.
• Upcoming data presentations will be held at the American Heart Association (AHA) in November 2023.

Negative

• Gross margin declined by 210 basis points in Q3 2023 compared to Q3 2022.

SAN FRANCISCO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023.

Third Quarter 2023 Financial Highlights

• Revenue of $124.6 million, a 20.0% increase compared to third quarter 2022
• Gross margin of 66.2%, a 210-basis point decline compared to third quarter 2022
• Cash, cash equivalents and marketable securities of $158.5 million as of September 30, 2023
• Increased fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million

Recent Operational Highlights

• Achieved record registration volumes during the quarter and launched next generation Zio monitor with enhanced Zio service that builds upon the strong historical performance of Zio XT
• Opened iRhythm’s Global Business Services center in the Philippines, positioning the company to maintain patient satisfaction, scale globally, and perform more efficiently
• mSToPs cost-effectiveness data published in Circulation: Cardiovascular Quality and Outcomes demonstrating that systematic screening for atrial fibrillation (AFib) with the iRhythm Zio XT patch provided high value from a health economic perspective
• Upcoming data presentations at the American Heart Association (AHA) in Philadelphia from November 11-13, 2023

"Building on momentum from the first half of 2023, our teams achieved record registration volumes in the third quarter," said Quentin Blackford, iRhythm’s President and CEO. "Revenue growth of 20% year-over-year was driven by strong volume contribution from accounts opened in the previous twelve months as well as sustained market penetration within our existing customer base. While we have been thrilled with the success that Zio XT has enjoyed in the marketplace, we are even more excited about the recent commercial launch of our next generation Zio monitor. With a smaller footprint, more breathable adhesive, and waterproof housing compared to Zio XT, the Zio monitor was designed with the patient in mind and embodies the next generation of ambulatory cardiac monitoring. We are also excited to have formally opened our Global Business Services center in the Philippines which will lead to meaningful operational efficiencies over time as we grow and scale our business."

"In addition to solid execution in our core commercial business, we are also very excited about the continued recognition from the scientific community of the compelling and differentiated value proposition that Zio offers. We are very pleased recently to have had the mSToPs cost-effectiveness analysis published, demonstrating that screening for atrial fibrillation (AFib) in individuals prescribed Zio XT patch monitors was associated with high economic value. With such incredible accomplishments over the past few months, I am encouraged by the continued execution against our long-range plan to capture our share of the immense opportunity in front of us today while also laying a solid foundation for significant profitable growth in the years to come," concluded Mr. Blackford.

Third Quarter Financial Results
Revenue for the third quarter of 2023 was $124.6 million, up 20.0% from $103.9 million during the same period in 2022. The increase was driven by growth in volume of Zio services, partially offset by a slight decline in average selling price.

Gross profit for the third quarter of 2023 was $82.5 million, up 16.3% from $70.9 million during the same period in 2022, while gross margin was 66.2%, down from 68.3% during the same period in 2022. The increase in gross profit was primarily due to increased volume of Zio services provided due to higher demand. The decrease in gross margin was primarily due to increased reserves for excess Zio XT printed circuit board assembly (PCBA) components recognized in the third quarter of 2023.

Operating expenses for the third quarter of 2023 were $110.1 million, compared to $92.0 million for the same period in 2022. Adjusted operating expenses for the third quarter of 2023 were $107.1 million, compared to $89.7 million during the same period in 2022. This increase in adjusted operating expenses resulted primarily from increased headcount-related costs to support growth in operations and to further development, enhancement, and functionality of our current and future product offerings as well as an increase in software and hardware costs to support growth in our infrastructure.

Net loss for the third quarter of 2023 was $27.1 million, or a diluted loss of $0.89 per share, compared with net loss of $21.5 million, or a diluted loss of $0.71 per share, for the same period in 2022. Adjusted net loss for the third quarter of 2023 was $24.1 million, or a diluted loss of $0.79 per share, compared with an adjusted net loss of $19.1 million, or a diluted loss of $0.63 per share, for the same period in 2022.

Cash, cash equivalents, and marketable securities were $158.5 million as of September 30, 2023.

2023 Annual Guidance
iRhythm projects revenue for the full year 2023 to grow approximately 19% compared to prior year results, ranging from approximately $487.5 million to $490 million. Gross margin for the full year 2023 is expected to range from 68% to 69% and adjusted operating expenses are expected to range between $425 million and $429 million. Adjusted EBITDA margin for the full year 2023 is expected to range from approximately 0% to 0.5% of revenues.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event, which will be available on the investors section of the Company’s website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share, and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures to their most directly comparable GAAP measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2023 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, income tax provision, impairment and restructuring charges, and business transformation costs.

We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:

• impairment and restructuring charges, and
• business transformation costs, which include one-time professional services and severance costs to augment and restructure the organization to use both outsourced and offshore resources.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about November 2, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
investors@irhythmtech.com

iRhythm Media Contact
Saige Smith
(262) 289-7065
irhythm@highwirepr.com

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)

	September 30, 2023				December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$	47,478			$	78,832
Marketable securities		110,995				134,312
Accounts receivable, net		50,067				49,918
Inventory		13,648				15,155
Prepaid expenses and other current assets		12,104				10,555
Total current assets		234,292				288,772
Property and equipment, net		96,668				75,670
Operating lease right-of-use assets		60,899				60,666
Goodwill		862				862
Other assets		47,048				22,252
Total assets	$	439,769			$	448,222
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	7,212			$	7,517
Accrued liabilities		76,631				65,497
Deferred revenue		3,383				3,051
Operating lease liabilities, current portion		15,065				13,031
Total current liabilities		102,291				89,096
Debt, noncurrent portion		34,946				34,935
Other noncurrent liabilities		1,013				1,307
Operating lease liabilities, noncurrent portion		81,724				83,072
Total liabilities		219,974				208,410
Stockholders’ equity:
Preferred stock		—				—
Common stock		31				28
Additional paid-in capital		826,686				762,380
Accumulated other comprehensive loss		(15	)			(396	)
Accumulated deficit		(606,907	)			(522,200	)
Total stockholders’ equity		219,795				239,812
Total liabilities and stockholders’ equity	$	439,769			$	448,222

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share data)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
Revenue, net	$	124,604			$	103,875			$	360,170			$	298,304
Cost of revenue		42,130				32,954				115,790				95,379
Gross profit		82,474				70,921				244,380				202,925
Operating expenses:
Research and development		16,309				11,448				44,828				33,935
Selling, general and administrative		93,768				80,559				285,531				235,468
Impairment and restructuring charges		—				—				—				26,608
Total operating expenses		110,077				92,007				330,359				296,011
Loss from operations		(27,603	)			(21,086	)			(85,979	)			(93,086	)
Interest expense		(927	)			(614	)			(2,709	)			(3,125	)
Interest and other income, net		1,609				365				4,476				450
Loss before income taxes		(26,921	)			(21,335	)			(84,212	)			(95,761	)
Income tax provision		195				116				495				196
Net loss	$	(27,116	)		$	(21,451	)		$	(84,707	)		$	(95,957	)
Net loss per common share, basic and diluted	$	(0.89	)		$	(0.71	)		$	(2.78	)		$	(3.22	)
Weighted-average shares, basic and diluted		30,607				30,055				30,470				29,837

IRHYTHM TECHNOLOGIES, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(unaudited)
(in thousands, except per share data)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
Adjusted EBITDA reconciliation
Net loss	$	(27,116	)		$	(21,451	)		$	(84,707	)		$	(95,957	)
Interest expense		927				614				2,709				3,125
Interest income		(1,717	)			(599	)			(4,619	)			(927	)
Income tax provision		195				116				495				196
Depreciation and amortization		4,067				3,436				11,434				9,930
Stock-based compensation		21,008				12,945				53,358				41,946
Impairment and restructuring charges		—				—				—				26,608
Business transformation costs		2,999				2,315				14,094				2,748
Adjusted EBITDA	$	363			$	(2,624	)		$	(7,236	)		$	(12,331	)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2023				2022				2023				2022
Adjusted net loss reconciliation
Net loss, as reported	$	(27,116	)		$	(21,451	)		$	(84,707	)		$	(95,957	)
Impairment and restructuring charges		—				—				—				26,608
Business transformation costs		2,999				2,315				14,094				2,748
Adjusted net loss	$	(24,117	)		$	(19,136	)		$	(70,613	)		$	(66,601	)
Adjusted net loss per share reconciliation
Net loss per share, as reported	$	(0.89	)		$	(0.71	)		$	(2.78	)		$	(3.22	)
Impairment and restructuring charges per share		—				—				—				0.89
Business transformation costs per share		0.10				0.08				0.46				0.09
Adjusted net loss per share	$	(0.79	)		$	(0.63	)		$	(2.32	)		$	(2.24	)
Weighted-average shares, basic and diluted		30,607				30,055				30,470				29,837
Adjusted operating expense reconciliation
Operating expense, as reported	$	110,077			$	92,007			$	330,359			$	296,011
Impairment and restructuring charges		—				—				—				(26,608	)
Business transformation costs		(2,999	)			(2,315	)			(14,094	)			(2,748	)
Adjusted operating expense	$	107,078			$	89,692			$	316,265			$	266,655

FAQ

What were iRhythm Technologies' Q3 2023 revenue?

iRhythm Technologies reported revenue of $124.6 million in Q3 2023.

What is iRhythm Technologies' fiscal year 2023 revenue guidance?

iRhythm Technologies increased its fiscal year 2023 revenue guidance to a range of $487.5 million to $490 million.

What were the recent operational highlights of iRhythm Technologies?

Recent operational highlights of iRhythm Technologies include achieving record registration volumes, launching the next generation Zio monitor with enhanced Zio service, opening a Global Business Services center in the Philippines, and publishing cost-effectiveness data for mSToPs.

Where will iRhythm Technologies present upcoming data?

iRhythm Technologies will present upcoming data at the American Heart Association (AHA) in November 2023.